**OOTWORACLE DAILY BRIEF — 27 April 2026**

**OOTWORACLE DAILY BRIEF — 27 April 2026**

**The Ibogaine Cardiac Reckoning**

Three independent papers on ibogaine's cardiac liability landed in the same 48-hour window. The timing is almost certainly coincidental; the implications are not. Taken together, the studies on QT prolongation, ventricular arrhythmia incidence, and unrecognized opioid use disorder in ibogaine-seeking populations constitute precisely the density of convergent safety signal that forces regulatory machinery into motion — whether or not the science ultimately supports the alarm.

The FDA's working model for managing novel-therapy cardiac risk is REMS. Esketamine's Spravato program, which mandates two-hour post-dose monitoring and certified facility requirements, added several hundred dollars per treatment episode in facility overhead and effectively restricted deployment to well-capitalized psychiatric practices. Ibogaine's cardiac profile is more acute than esketamine's dissociation risk by any reasonable clinical measure. ECG monitoring, arrhythmia response capacity, and cardiologist sign-off are not equivalent burdens to a supervised waiting room. The veterans' advocate community, which has been ibogaine's most effective political constituency, understands this arithmetic and is quietly alarmed — the treatment that works for their members may be about to become inaccessible for structural rather than clinical reasons.

The five-agent simulation consensus on this point (with only the veterans' advocate and clinical researcher dissenting) reflects a genuine professional judgment: the question is not whether cardiac monitoring requirements will be imposed, but how burdensome they will be and whether the humanitarian unmet-need argument — opioid use disorder kills 80,000 Americans annually — can move the needle in an FDA advisory committee setting. That committee review is now the most likely formal resolution mechanism, probable sometime in 2027.

Meanwhile, the ibogaine debate is about to undergo a secondary transformation: from a clinical question into a culture war exhibit. Both the pro-supervised-access camp and the anti-psychedelic camp now have genuine evidence for their priors. The science supports cardiac screening as a management solution; it also supports the claim that cardiac screening will fail in real-world deployment. Both readings are defensible. Both will be amplified. The nuance — that ibogaine is dangerous without protocols and potentially life-saving with them — will not survive the translation into political media.

Elsewhere, the psilocybin trajectory continues to look like the cleanest path to the first classic psychedelic FDA approval. The EPISODE trial data has no cardiac analogue, no scheduling complexity inherited from MDMA's political baggage, and is accumulating Phase 3-quality evidence across multiple independent sponsors. An NDA acceptance for treatment-resistant MDD by Q2 2028 remains the modal outcome at 0.74 confidence — the primary risk being whether EPISODE's 12-month durability data, expected within 18 months, holds above the threshold that would satisfy cautious reviewers. Compass Pathways' Breakthrough Therapy designation for COMP360 creates a regulatory runway that is, by psychedelic standards, remarkably unobstructed.

A quieter but methodologically significant signal: new preclinical data on the differential effects of acute versus chronic fluoxetine exposure on psychedelic pharmacodynamics raises a trial validity problem that the FDA will eventually have to address formally. With SSRIs prescribed to roughly 13% of U.S. adults and treatment-resistant MDD patients likely disproportionately represented in prior SSRI use, the question of standardized washout criteria is not academic. Expect this to appear in FDA guidance or advisory committee requirements within 24 months of the first psilocybin NDA submission.

The market read today — CMPS -6.8%, ATAI -4.2% — reflects investor pricing of the ibogaine overhang onto the broader psychedelic equity basket. That conflation is analytically imprecise. The cardiac risk that burdens ibogaine is structurally absent from the psilocybin and classic serotonergic pathways. But in a sector where investor sentiment drives research funding, imprecise conflation has real consequences. The ibogaine cardiac story will be used as evidence for contradictory conclusions for at least the next 18 months. That, more than any single regulatory decision, is today's most durable signal.